Business News • PR NewsWire • CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

SHANGHAI, Aug. 30, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell...

View More : https://www.prnewswire.com:443/news-releases/carsgen-therapeutics-receives-us-fda-orphan-drug-designation-for-fully-huma...

Releted News by prnewswire

Ping An Property Insurance to Attend WAIC 2019 with its Latest AI Innovations, Accelerating Industry Transformation

CAPITAL ONE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Capital One Financial Corporation - COF

Finquest gibt die Eröffnung eines neuen Büros in Paris bekannt

Finquest annonce l'ouverture d'un nouveau bureau à Paris